期刊文献+

多药耐药基因多态性和单倍体对肾移植患者他克莫司血药浓度的影响 被引量:3

Influence of multidrug resistant gene polymorphisms and haplotype on blood concentration of tacrolimus in renal transplant patients
下载PDF
导出
摘要 目的研究多药耐药基因(MDR1)单核苷酸多态性及单倍体对中国汉族肾脏移植人群术后稳定期与他克莫司(免疫抑制剂)血药浓度的关系。方法用基质辅助激光吸收电离子化-飞行时间质谱技术,分析63例肾移植患者的MDR1 exon12 C1236T、exon 21 G2677T/A、exon 26 C3435T的基因型,结合其口服他克莫司12 h后血药浓度,判断两者是否存在关联。结果 MDR1 C3435T基因多态性与他克莫司血药浓度/(剂量×体表面积)具有相关性,比值由小到大顺序:野生型纯合子<杂合子<突变型纯合子,差异具有统计学意义(P<0.05)。MDR1 C1236T、G2677T/A及单倍体型各组之间比较均无明显差异。结论中国汉族肾移植患者稳定期,MDR1 C3435T与他克莫司血药浓度的个体差异具有相关性。 Objective To evaluate retrospectively the effects of genetic polymorphisms in exon 12 C1236T , exon 21 and exon 26 C3435T of multidrug resistant gene( MDR1 ) gene on blood concentration of tacroli- mus in Chinese renal transplant patients in stable stage after renal trans- plantation. Methods Time- of flight mass spectrometry was used to a- nalysis the target genetic polymorphisms from 63 Chinese Han patients af- ter renal transplantation. Concentration of tacrolimus was detected 12 h after oral application. Then the relationship between them was estimated. Results A correlation was found between the concentration /( dose x surface area) ratio and the SNPS of C3435T (P 〈 0. 05 ) , the ratio in- creased as follows: wild -type homozygote 〈 heterozygote 〈 mutant ho- mozygote. No difference was found among the MDR1 G2677T/A, C1236T, haploid genotypes and the ratio. Conclusion It was demon- strates that genetic polymorphism of MDR1 C3435T is correlated with the whole blood concentration/'( dose x surface area) of tacrolimus in Chinese renal transplant patients in stable stage.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2010年第9期643-646,共4页 The Chinese Journal of Clinical Pharmacology
基金 常州市科技局指导性基金资助项目(CS2008901)
关键词 多药耐药基因 单倍体 他克莫司 飞行时间质谱 multidrug resistant gene haplotype tacrolimus time - of flight mass spectrometry
  • 相关文献

参考文献5

二级参考文献29

  • 1焦正,梁惠琪,丁俊杰,李中东,施孝金,钟明康.MDR1基因多态性对口服环孢素A药代动力学的影响[J].药学学报,2004,39(12):971-974. 被引量:10
  • 2Yong Yong SHI,Lin HE.SHEsis,a powerful software platform for analyses of linkage disequilibrium,haplotype construction,and genetic association at polymorphism loci[J].Cell Research,2005,15(2):97-98. 被引量:382
  • 3Waddell S,Chin J Physiol Sci,1928年,1期,25页
  • 4Mahalati K, Belitsky P, Sketris I et al.Neoral monitoring by simplified sparse sampling area under the concentration-time curve[J].Transplantation,1999,68(1):55-62.
  • 5Kahan BD, Keown P, Levy GA et al.Therapeutic drug monitoring of immunosuppressant drugs in clinical practice[J].Clin Ther,2002,24(3):330-50,discussion 329.
  • 6Keown PA. New concepts in cyclosporine monitoring[J].Curr Opin Nephrol Hypertens,2002,11(6):619-29.
  • 7Evans WE, McLeod HL. Pharmacogenomics-Drug disposition, drug targets and side effect[J].N Engl J Med, 2003,348(6):538-49.
  • 8Weinshilboum R. Inheritance and drug response[J].N Engl J Med, 2003,348(6):529-37.
  • 9Zhu B, Liu ZQ, Chen GL et al.The distribution and gender difference of CYP3A activity in Chinese subjects[J].Br J Clin Pharmacol,2003,55(3):264-9.
  • 10Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J].Nat Genet,2001,27(4):383-91.

共引文献383

同被引文献92

  • 1焦正,杨洁,张明,施孝金.高效液相色谱法测定人血浆中咪唑立宾的浓度[J].中国新药与临床杂志,2006,25(7):489-491. 被引量:10
  • 2肖力,任斌,陈小陆.荧光偏振法测定去甲万古霉素血药浓度[J].齐齐哈尔医学院学报,2007,28(3):315-316. 被引量:9
  • 3Oellerich M, Hon, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments [ J ]. Ther Drug Monit, 2006,28(6) :720-725.
  • 4Khoschsorur G, Fruehwirth F, Zelzer S, et al. comparison of fluorescent polarization immunoassay ( FPIA ) versus HPLC to measure everolimus blood concentrations in clin- ical transplantation [ J ]. Clin Chim Acta, 2007,380 ( 1/ 2) :217-221.
  • 5Taylor PJ, Franklin ME, Graham KS, et al. A HPLC-mass spectrometric method suitable for the therapeutic drug mo- nitoring of everolimus [ J ]. J Chromatogr B, 2007,848 (2) :208-214.
  • 6Einecke G, Mai I, Fritsche L, et al. the value of C2 moni- toring in stable renal allograft recipients on maintenance immunosuppression [ J ]. Nephrol Dial Transplant, 2004, 19( 1 ) :215-222.
  • 7Umezawa Y, Ozawa A. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis [ J ]. Int J Dermato1,2007,46 ( 7 ) : 763-766.
  • 8Mathew BS, Fleming DH, Jeyaseelan V, et al. Alimited sampling strategy for tacrolimus in renal transplant pa- tients [ J ]. Br J Clin Pharmacol, 2008,66 (4) :467-472.
  • 9Crettol S, Venetz J-P, Fontana M ,et al.CYP3A7, CYP3A5, CYP'3A4 and ABCBlgenetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipi-ents [ J ]. Ther Drug Monit,2008,30 (6) :689-699.
  • 10Trevillian P. The CARI guidelines, calcineurin inhibitors in renal transplantation [ J ]. Nephrology, 2007,12 : S57-S65.

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部